» Articles » PMID: 33639215

MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants Through in Vitro CRISPR/Cas9 Cleavage

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2021 Feb 27
PMID 33639215
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccinia virus (VACV)-based vectors are in extensive use as vaccines and cancer immunotherapies. VACV engineering has traditionally relied on homologous recombination between a parental viral genome and a transgene-bearing transfer plasmid, an inefficient process that necessitates the use of a selection or screening marker to isolate recombinants. Recent extensions of this approach have sought to enhance the recovery of transgene-bearing viruses through the use of CRISPR-Cas9 engineering to cleave the viral genome in infected cells. However, these methods do not completely eliminate the generation of WT viral progeny and thus continue to require multiple rounds of viral propagation and plaque purification. Here, we describe MAVERICC (marker-free vaccinia virus engineering of recombinants through in vitroCRISPR/Cas9 cleavage), a new strategy to engineer recombinant VACVs in a manner that overcomes current limitations. MAVERICC also leverages the CRISPR/Cas9 system but requires no markers and yields essentially pure preparations of the desired recombinants in a single step. We used this approach to introduce point mutations, insertions, and deletions at multiple locations in the VACV genome, both singly and in combination. The efficiency and versatility of MAVERICC make it an ideal choice for generating mutants and mutant libraries at arbitrarily selected locations in the viral genome to build complex VACV vectors, effect vector improvements, and facilitate the study of poxvirus biology.

Citing Articles

Structural insights into tecovirimat antiviral activity and poxvirus resistance.

Vernuccio R, Martinez Leon A, Poojari C, Buchrieser J, Selverian C, Jaleta Y Nat Microbiol. 2025; 10(3):734-748.

PMID: 39939832 PMC: 11879855. DOI: 10.1038/s41564-025-01936-6.


Cas9-Mediated Poxvirus Recombinant Recovery (CASPRR) for Fast Recovery of Recombinant Vaccinia Viruses.

Gowripalan A, Smith S, Tscharke D Methods Mol Biol. 2024; 2860:115-130.

PMID: 39621264 DOI: 10.1007/978-1-0716-4160-6_8.


Rapid Generation of Recombinant Poxviruses Using CRISPR/Cas9 Gene Editing.

Lin Y, Evans D, Noyce R Methods Mol Biol. 2024; 2860:97-114.

PMID: 39621263 DOI: 10.1007/978-1-0716-4160-6_7.


Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies.

Banda A, Impomeni O, Singh A, Baloch A, Hu W, Jaijyan D Vaccines (Basel). 2024; 12(6).

PMID: 38932365 PMC: 11209408. DOI: 10.3390/vaccines12060636.


Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances.

Wang Y Viruses. 2023; 15(8).

PMID: 37632084 PMC: 10457812. DOI: 10.3390/v15081742.


References
1.
Okoli A, Okeke M, Tryland M, Moens U . CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development. Viruses. 2018; 10(1). PMC: 5795463. DOI: 10.3390/v10010050. View

2.
Smith G, Moss B . Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene. 1983; 25(1):21-8. DOI: 10.1016/0378-1119(83)90163-4. View

3.
Meyer H, Damon I, Esposito J . Orthopoxvirus diagnostics. Methods Mol Biol. 2004; 269:119-34. DOI: 10.1385/1-59259-789-0:119. View

4.
Maki J, Guiot A, Aubert M, Brochier B, Cliquet F, Hanlon C . Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG): a global review. Vet Res. 2017; 48(1):57. PMC: 5610451. DOI: 10.1186/s13567-017-0459-9. View

5.
Concordet J, Haeussler M . CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018; 46(W1):W242-W245. PMC: 6030908. DOI: 10.1093/nar/gky354. View